Endocannabinoids in Multiple Sclerosis and ALS: From Symptom Relief to Neuroprotection
Research showed cannabinoids can relieve MS spasticity and may also slow neurodegeneration in both MS and ALS animal models, suggesting potential beyond symptom management.
Quick Facts
What This Study Found
This review examined the role of the endocannabinoid system in multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS), two neurodegenerative conditions sharing the symptom of spasticity.
Anecdotal reports of cannabis relieving MS symptoms were confirmed by animal models and clinical trials, leading to the approval of medicinal cannabis (nabiximols) for MS spasticity. Beyond symptom relief, experimental studies showed cannabinoids had neuroprotective effects in animal models of both MS and ALS.
The neuroprotective potential was particularly notable: cannabinoids appeared to slow neurodegeneration rather than just masking symptoms. This suggested the endocannabinoid system could be a target for disease-modifying therapies, not just symptom control.
Key Numbers
Nabiximols approved for MS spasticity; neuroprotective effects demonstrated in animal models of MS and ALS; endocannabinoid system components identified as potential disease-modifying targets
How They Did This
Review of published preclinical and clinical evidence on the endocannabinoid system in MS and ALS, published in the Handbook of Experimental Pharmacology.
Why This Research Matters
While cannabis-based medicines are approved for MS symptom management, the possibility that they could also slow disease progression would represent a fundamental shift from palliative to disease-modifying therapy.
The Bigger Picture
If cannabinoids can both relieve symptoms and protect nerves, they could serve dual purposes in neurodegenerative disease. However, translating neuroprotective effects from animal models to human clinical benefit remains one of the biggest challenges in neuroscience.
What This Study Doesn't Tell Us
Neuroprotective effects were primarily from animal models. Human clinical evidence for disease modification was limited. MS and ALS have different pathologies, and cannabinoid effects may differ between them.
Questions This Raises
- ?Can the neuroprotective effects seen in animals be demonstrated in human clinical trials?
- ?Would long-term cannabinoid use slow MS or ALS progression?
- ?Is the neuroprotective mechanism CB1-mediated, CB2-mediated, or both?
Trust & Context
- Key Stat:
- Neuroprotective effects in animal models of both MS and ALS
- Evidence Grade:
- Review in a reference pharmacology handbook. Symptom relief evidence is established; neuroprotective evidence is primarily preclinical.
- Study Age:
- Published in 2015. Clinical trials of cannabinoids for neuroprotection in MS continue.
- Original Title:
- Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis.
- Published In:
- Handbook of experimental pharmacology, 231, 213-31 (2015)
- Authors:
- Pryce, Gareth(10), Baker, David(10)
- Database ID:
- RTHC-01043
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can cannabis slow down MS?
Animal studies suggest cannabinoids may have neuroprotective effects that could slow disease progression. However, this has not been definitively proven in human clinical trials. Currently approved cannabinoid treatments for MS target symptoms, primarily spasticity.
Does cannabis help with ALS?
In animal models of ALS, cannabinoids showed neuroprotective effects. Human evidence is very limited. People with ALS sometimes use cannabis for symptom relief (spasticity, pain), but disease-modifying effects have not been established.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01043APA
Pryce, Gareth; Baker, David. (2015). Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis.. Handbook of experimental pharmacology, 231, 213-31. https://doi.org/10.1007/978-3-319-20825-1_7
MLA
Pryce, Gareth, et al. "Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis.." Handbook of experimental pharmacology, 2015. https://doi.org/10.1007/978-3-319-20825-1_7
RethinkTHC
RethinkTHC Research Database. "Endocannabinoids in Multiple Sclerosis and Amyotrophic Later..." RTHC-01043. Retrieved from https://rethinkthc.com/research/pryce-2015-endocannabinoids-in-multiple-sclerosis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.